182 related articles for article (PubMed ID: 10808211)
21. Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.
Tiersten A; Wo J; Jacobson C; Weitzman A; Horwich T; Hesdorffer C; Savage D; Troxel A
Breast; 2004 Aug; 13(4):341-6. PubMed ID: 15325671
[TBL] [Abstract][Full Text] [Related]
22. Busulfan and cyclophosphamide (Bu/Cy) as a preparative regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma: a single-institution experience.
Ulrickson M; Aldridge J; Kim HT; Hochberg EP; Hammerman P; Dube C; Attar E; Ballen KK; Dey BR; McAfee SL; Spitzer TR; Chen YB
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1447-54. PubMed ID: 19822305
[TBL] [Abstract][Full Text] [Related]
23. Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction.
Fujimaki K; Maruta A; Yoshida M; Sakai R; Tanabe J; Koharazawa H; Kodama F; Asahina S; Minamizawa M; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
Bone Marrow Transplant; 2001 Feb; 27(3):307-10. PubMed ID: 11277179
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation.
Solano C; Badia B; Lluch A; Marugan I; Benet I; Arbona C; Prosper F; García-Conde J
Bone Marrow Transplant; 2001 Feb; 27(3):287-93. PubMed ID: 11277176
[TBL] [Abstract][Full Text] [Related]
25. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.
Lind PA; Marks LB; Jamieson TA; Carter DL; Vredenburgh JJ; Folz RJ; Prosnitz LR
Cancer; 2002 Jun; 94(11):2821-9. PubMed ID: 12115368
[TBL] [Abstract][Full Text] [Related]
26. Prolonged survival of patients with angioimmunoblastic T-cell lymphoma after high-dose chemotherapy and autologous stem cell transplantation: the GELTAMO experience.
Rodríguez J; Conde E; Gutiérrez A; Arranz R; Gandarillas M; Leon A; Ojanguren J; Sureda A; Carrera D; Bendandi M; Moraleda J; Ribera JM; Albo C; Morales A; García JC; Fernández P; Cañigral G; Bergua J; Caballero MD;
Eur J Haematol; 2007 Apr; 78(4):290-6. PubMed ID: 17378891
[TBL] [Abstract][Full Text] [Related]
27. Cardiac toxicity associated with anthracycline-containing chemotherapy in older women with breast cancer.
Du XL; Xia R; Liu CC; Cormier JN; Xing Y; Hardy D; Chan W; Burau K
Cancer; 2009 Nov; 115(22):5296-308. PubMed ID: 19672997
[TBL] [Abstract][Full Text] [Related]
28. Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality. The University of Nebraska Medical Center Bone Marrow Transplantation Pulmonary Study Group.
Jain B; Floreani AA; Anderson JR; Vose JM; Robbins RA; Rennard SI; Sisson JH
Bone Marrow Transplant; 1996 Apr; 17(4):561-8. PubMed ID: 8722355
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
[TBL] [Abstract][Full Text] [Related]
30. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.
Cao TM; Negrin RS; Stockerl-Goldstein KE; Johnston LJ; Shizuru JA; Taylor TL; Rizk NW; Wong RM; Blume KG; Hu WW
Biol Blood Marrow Transplant; 2000; 6(4):387-94. PubMed ID: 10917574
[TBL] [Abstract][Full Text] [Related]
31. Quality of life in patients surviving at least 12 months following high dose chemotherapy with autologous bone marrow support.
Winer EP; Lindley C; Hardee M; Sawyer WT; Brunatti C; Borstelmann NA; Peters W
Psychooncology; 1999; 8(2):167-76. PubMed ID: 10335560
[TBL] [Abstract][Full Text] [Related]
32. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
33. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
Lyman GH; Dale DC; Crawford J
J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
[TBL] [Abstract][Full Text] [Related]
35. Serious cardiac complications during bone marrow transplantation at the University of Minnesota, 1977-1997.
Murdych T; Weisdorf DJ
Bone Marrow Transplant; 2001 Aug; 28(3):283-7. PubMed ID: 11535997
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
Cairoli R; Grillo G; Tedeschi A; Gargantini L; Marenco P; Tresoldi E; Barbarano L; Nosari AM; Morra E
Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
[TBL] [Abstract][Full Text] [Related]
37. Feasibility and toxicity of high-dose chemotherapy supported by peripheral blood stem cell transplantation in elderly patients (>/=60 years) with non-Hodgkin's lymphoma: comparison with patients <60 years treated within the same protocol.
Jantunen E; Mahlamäki E; Nousiainen T
Bone Marrow Transplant; 2000 Oct; 26(7):737-41. PubMed ID: 11042654
[TBL] [Abstract][Full Text] [Related]
38. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
[TBL] [Abstract][Full Text] [Related]
39. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens.
Genre D; Viens P; Bertucci F; Chabannon C; Gravis G; Braud AC; Camerlo J; Houvenaeghel G; Moutardier V; Goncalvez A; Protière C; Bardou VJ; Maraninchi D
Bone Marrow Transplant; 2002 Jun; 29(11):881-6. PubMed ID: 12080351
[TBL] [Abstract][Full Text] [Related]
40. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer.
Porrata LF; Ingle JN; Litzow MR; Geyer S; Markovic SN
Bone Marrow Transplant; 2001 Nov; 28(9):865-71. PubMed ID: 11781647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]